Dyslipidemia in children with chronic kidney disease—findings from the Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study

go back to reference Saland JM, Kupferman JC, Pierce CB, Flynn JT, Mitsnefes MM, Warady BA, Furth SL (2019) Change in dyslipidemia with declining glomerular filtration rate and increasing proteinuria in children with CKD. Clin J Am Soc Nephrol 14:1711–1718PubMedPubMedCentralCrossRef Saland JM, Kupferman JC, Pierce CB, Flynn JT, Mitsnefes MM, Warady BA, Furth SL (2019) Change in dyslipidemia with declining glomerular filtration rate and increasing proteinuria in children with CKD. Clin J Am Soc Nephrol 14:1711–1718PubMedPubMedCentralCrossRef

go back to reference Khurana M, Silverstein DM (2015) Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol 30:2073–2084PubMedCrossRef Khurana M, Silverstein DM (2015) Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol 30:2073–2084PubMedCrossRef

go back to reference Moradi H, Vaziri ND (2018) Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease. Front Biosci (Landmark Ed) 23:146–161PubMedCrossRef Moradi H, Vaziri ND (2018) Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease. Front Biosci (Landmark Ed) 23:146–161PubMedCrossRef

go back to reference Saland JM, Pierce CB, Mitsnefes MM, Flynn JT, Goebel J, Kupferman JC, Warady BA, Furth SL, CKiD Investigators (2010) Dyslipidemia in children with chronic kidney disease. Kidney Int 78:1154–1163PubMedPubMedCentralCrossRef Saland JM, Pierce CB, Mitsnefes MM, Flynn JT, Goebel J, Kupferman JC, Warady BA, Furth SL, CKiD Investigators (2010) Dyslipidemia in children with chronic kidney disease. Kidney Int 78:1154–1163PubMedPubMedCentralCrossRef

go back to reference Baek HS, Kim SH, Kang HG, Choi HJ, Cheong HI, Ha IS, Han KH, Cho HY, Shin JI, Park YS, Lee JH, Ahn YH, Park E, Cho MH (2020) Dyslipidemia in pediatric CKD patients: results from KNOW-PedCKD (KoreaN cohort study for outcomes in patients with pediatric CKD). Pediatr Nephrol 35:1455–1461PubMedCrossRef Baek HS, Kim SH, Kang HG, Choi HJ, Cheong HI, Ha IS, Han KH, Cho HY, Shin JI, Park YS, Lee JH, Ahn YH, Park E, Cho MH (2020) Dyslipidemia in pediatric CKD patients: results from KNOW-PedCKD (KoreaN cohort study for outcomes in patients with pediatric CKD). Pediatr Nephrol 35:1455–1461PubMedCrossRef

go back to reference Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578–585PubMedPubMedCentralCrossRef Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578–585PubMedPubMedCentralCrossRef

go back to reference Saland JM, Ginsberg H, Fisher EA (2002) Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr 14:197–204PubMedCrossRef Saland JM, Ginsberg H, Fisher EA (2002) Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr 14:197–204PubMedCrossRef

go back to reference de Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, Mietus-Snyder M, Mitsnefes MM, Peterson AL, St-Pierre J, Urbina EM, Zachariah JP, Zaidi AN (2019) Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. Circulation 139:e603–e634PubMedCrossRef de Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, Mietus-Snyder M, Mitsnefes MM, Peterson AL, St-Pierre J, Urbina EM, Zachariah JP, Zaidi AN (2019) Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. Circulation 139:e603–e634PubMedCrossRef

go back to reference Querfeld U, Anarat A, Bayazit AK, Bakkaloglu AS, Bilginer Y, Caliskan S, Civilibal M, Doyon A, Duzova A, Kracht D, Litwin M, Melk A, Mir S, Sozeri B, Shroff R, Zeller R, Wuhl E, Schaefer F; 4C Study Group (2010) The cardiovascular comorbidity in children with chronic kidney disease (4C) study: objectives, design, and methodology. Clin J Am Soc Nephrol 5:1642–1648PubMedPubMedCentralCrossRef Querfeld U, Anarat A, Bayazit AK, Bakkaloglu AS, Bilginer Y, Caliskan S, Civilibal M, Doyon A, Duzova A, Kracht D, Litwin M, Melk A, Mir S, Sozeri B, Shroff R, Zeller R, Wuhl E, Schaefer F; 4C Study Group (2010) The cardiovascular comorbidity in children with chronic kidney disease (4C) study: objectives, design, and methodology. Clin J Am Soc Nephrol 5:1642–1648PubMedPubMedCentralCrossRef

go back to reference Schaefer F, Doyon A, Azukaitis K, Bayazit A, Canpolat N, Duzova A, Niemirska A, Sozeri B, Thurn D, Anarat A, Ranchin B, Litwin M, Caliskan S, Candan C, Baskin E, Yilmaz E, Mir S, Kirchner M, Sander A, Haffner D, Melk A, Wuhl E, Shroff R, Querfeld U, 4C Study Consortium (2017) Cardiovascular phenotypes in children with CKD: the 4C study. Clin J Am Soc Nephrol 12:19–28PubMedCrossRef Schaefer F, Doyon A, Azukaitis K, Bayazit A, Canpolat N, Duzova A, Niemirska A, Sozeri B, Thurn D, Anarat A, Ranchin B, Litwin M, Caliskan S, Candan C, Baskin E, Yilmaz E, Mir S, Kirchner M, Sander A, Haffner D, Melk A, Wuhl E, Shroff R, Querfeld U, 4C Study Consortium (2017) Cardiovascular phenotypes in children with CKD: the 4C study. Clin J Am Soc Nephrol 12:19–28PubMedCrossRef

go back to reference Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute (2011) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128(Suppl 5):S213–S256PubMedCentral Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute (2011) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128(Suppl 5):S213–S256PubMedCentral

go back to reference Bonthuis M, van Stralen KJ, Verrina E, Edefonti A, Molchanova EA, Hokken-Koelega AC, Schaefer F, Jager KJ (2012) Use of national and international growth charts for studying height in European children: development of up-to-date European height-for-age charts. PLoS One 7:e42506PubMedPubMedCentralCrossRef Bonthuis M, van Stralen KJ, Verrina E, Edefonti A, Molchanova EA, Hokken-Koelega AC, Schaefer F, Jager KJ (2012) Use of national and international growth charts for studying height in European children: development of up-to-date European height-for-age charts. PLoS One 7:e42506PubMedPubMedCentralCrossRef

go back to reference National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRef National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRef

go back to reference Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830CrossRef Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830CrossRef

go back to reference Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D, International Pediatric Nephrology Association (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877–919PubMedCrossRef Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D, International Pediatric Nephrology Association (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877–919PubMedCrossRef

go back to reference Stoycheff N, Stevens LA, Schmid CH, Tighiouart H, Lewis J, Atkins RC, Levey AS (2009) Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the definition. Am J Kidney Dis 54:840–849PubMedPubMedCentralCrossRef Stoycheff N, Stevens LA, Schmid CH, Tighiouart H, Lewis J, Atkins RC, Levey AS (2009) Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the definition. Am J Kidney Dis 54:840–849PubMedPubMedCentralCrossRef

go back to reference Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, Kahn SE, Pfarr E, Schnaidt S, von Eynatten M, George JT, Gollop ND, Marx N, Alexander JH, Zinman B, Perkovic V, CARMELINA investigators (2021) Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. Clin Kidney J 14:226–236PubMedPubMedCentralCrossRef Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, Kahn SE, Pfarr E, Schnaidt S, von Eynatten M, George JT, Gollop ND, Marx N, Alexander JH, Zinman B, Perkovic V, CARMELINA investigators (2021) Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. Clin Kidney J 14:226–236PubMedPubMedCentralCrossRef

go back to reference Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637PubMedPubMedCentralCrossRef Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637PubMedPubMedCentralCrossRef

go back to reference Khandelwal P, Murugan V, Hari S, Lakshmy R, Sinha A, Hari P, Bagga A (2016) Dyslipidemia, carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol 31:1313–1320PubMedCrossRef Khandelwal P, Murugan V, Hari S, Lakshmy R, Sinha A, Hari P, Bagga A (2016) Dyslipidemia, carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol 31:1313–1320PubMedCrossRef

go back to reference Langsted A, Nordestgaard BG (2019) Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology 51:131–141PubMedCrossRef Langsted A, Nordestgaard BG (2019) Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology 51:131–141PubMedCrossRef

go back to reference Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Boren J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M, European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative (2016) Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 37:1944–1958PubMedPubMedCentralCrossRef Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Boren J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M, European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative (2016) Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 37:1944–1958PubMedPubMedCentralCrossRef

go back to reference Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA (2001) Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 59:179–189PubMedCrossRef Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA (2001) Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 59:179–189PubMedCrossRef

go back to reference Shearer GC, Kaysen GA (2006) Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion. Kidney Int 70:647–653PubMedCrossRef Shearer GC, Kaysen GA (2006) Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion. Kidney Int 70:647–653PubMedCrossRef

go back to reference Lamb EJ, MacKenzie F, Stevens PE (2009) How should proteinuria be detected and measured? Ann Clin Biochem 46:205–217PubMedCrossRef Lamb EJ, MacKenzie F, Stevens PE (2009) How should proteinuria be detected and measured? Ann Clin Biochem 46:205–217PubMedCrossRef

go back to reference Kim HJ, Kang E, Ryu H, Han M, Lee KB, Kim YS, Sung S, Ahn C, Oh KH (2019) Metabolic acidosis is associated with pulse wave velocity in chronic kidney disease: results from the KNOW-CKD Study. Sci Rep 9:16139PubMedPubMedCentralCrossRef Kim HJ, Kang E, Ryu H, Han M, Lee KB, Kim YS, Sung S, Ahn C, Oh KH (2019) Metabolic acidosis is associated with pulse wave velocity in chronic kidney disease: results from the KNOW-CKD Study. Sci Rep 9:16139PubMedPubMedCentralCrossRef

go back to reference Dobre M, Yang W, Pan Q, Appel L, Bellovich K, Chen J, Feldman H, Fischer MJ, Ham LL, Hostetter T, Jaar BG, Kallem RR, Rosas SE, Scialla JJ, Wolf M, Rahman M, CRIC Study Investigators (2015) Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): a report from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Heart Assoc 4:e001599PubMedPubMedCentralCrossRef Dobre M, Yang W, Pan Q, Appel L, Bellovich K, Chen J, Feldman H, Fischer MJ, Ham LL, Hostetter T, Jaar BG, Kallem RR, Rosas SE, Scialla JJ, Wolf M, Rahman M, CRIC Study Investigators (2015) Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): a report from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Heart Assoc 4:e001599PubMedPubMedCentralCrossRef

go back to reference de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20:2075–2084PubMedPubMedCentralCrossRef de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20:2075–2084PubMedPubMedCentralCrossRef

go back to reference Capusa C, Stefan G, Stancu S, Lipan M, Tsur LD, Mircescu G (2017) Metabolic acidosis of chronic kidney disease and subclinical cardiovascular disease markers: friend or foe? Medicine (Baltimore) 96:e8802PubMedCrossRef Capusa C, Stefan G, Stancu S, Lipan M, Tsur LD, Mircescu G (2017) Metabolic acidosis of chronic kidney disease and subclinical cardiovascular disease markers: friend or foe? Medicine (Baltimore) 96:e8802PubMedCrossRef

go back to reference Carrero JJ, Hecking M, Chesnaye NC, Jager KJ (2018) Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol 14:151–164PubMedCrossRef Carrero JJ, Hecking M, Chesnaye NC, Jager KJ (2018) Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol 14:151–164PubMedCrossRef

go back to reference Ruebner RL, Ng D, Mitsnefes M, Foster BJ, Meyers K, Warady B, Furth SL (2016) Cardiovascular disease risk factors and left ventricular hypertrophy in girls and boys with CKD. Clin J Am Soc Nephrol 11:1962–1968PubMedPubMedCentralCrossRef Ruebner RL, Ng D, Mitsnefes M, Foster BJ, Meyers K, Warady B, Furth SL (2016) Cardiovascular disease risk factors and left ventricular hypertrophy in girls and boys with CKD. Clin J Am Soc Nephrol 11:1962–1968PubMedPubMedCentralCrossRef

go back to reference Lamprea-Montealegre JA, Astor BC, McClelland RL, de Boer IH, Burke GL, Sibley CT, O’Leary D, Sharrett AR, Szklo M (2012) CKD, plasma lipids, and common carotid intima-media thickness: results from the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 7:1777–1785PubMedPubMedCentralCrossRef Lamprea-Montealegre JA, Astor BC, McClelland RL, de Boer IH, Burke GL, Sibley CT, O’Leary D, Sharrett AR, Szklo M (2012) CKD, plasma lipids, and common carotid intima-media thickness: results from the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 7:1777–1785PubMedPubMedCentralCrossRef

go back to reference Mak RH (2024) Protein energy wasting in children with chronic kidney disease: is lean body mass by DEXA a key diagnostic biomarker? Pediatr Nephrol 39:1323–1326PubMedCrossRef Mak RH (2024) Protein energy wasting in children with chronic kidney disease: is lean body mass by DEXA a key diagnostic biomarker? Pediatr Nephrol 39:1323–1326PubMedCrossRef

go back to reference Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ (2003) Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl:S121–124 Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ (2003) Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl:S121–124

go back to reference Clement LC, Mace C, Avila-Casado C, Joles JA, Kersten S, Chugh SS (2014) Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 20:37–46PubMedCrossRef Clement LC, Mace C, Avila-Casado C, Joles JA, Kersten S, Chugh SS (2014) Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 20:37–46PubMedCrossRef

go back to reference Vianna HR, Soares CM, Silveira KD, Elmiro GS, Mendes PM, de Sousa TM, Teixeira MM, Miranda DM, Simoes ESAC (2013) Cytokines in chronic kidney disease: potential link of MCP-1 and dyslipidemia in glomerular diseases. Pediatr Nephrol 28:463–469PubMedCrossRef Vianna HR, Soares CM, Silveira KD, Elmiro GS, Mendes PM, de Sousa TM, Teixeira MM, Miranda DM, Simoes ESAC (2013) Cytokines in chronic kidney disease: potential link of MCP-1 and dyslipidemia in glomerular diseases. Pediatr Nephrol 28:463–469PubMedCrossRef

go back to reference Low LD, Lu L, Chan CY, Chen J, Yang HH, Yu H, Lee CGL, Ng KH, Yap HK (2020) IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease. Clin Sci (Lond) 134:225–237PubMedCrossRef Low LD, Lu L, Chan CY, Chen J, Yang HH, Yu H, Lee CGL, Ng KH, Yap HK (2020) IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease. Clin Sci (Lond) 134:225–237PubMedCrossRef

go back to reference Attman PO, Alaupovic P, Tavella M, Knight-Gibson C (1996) Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 11:63–69PubMedCrossRef Attman PO, Alaupovic P, Tavella M, Knight-Gibson C (1996) Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 11:63–69PubMedCrossRef

go back to reference Chen H, Chen L, Liu D, Chen DQ, Vaziri ND, Yu XY, Zhang L, Su W, Bai X, Zhao YY (2017) Combined clinical phenotype and lipidomic analysis reveals the impact of chronic kidney disease on lipid metabolism. J Proteome Res 16:1566–1578PubMedCrossRef Chen H, Chen L, Liu D, Chen DQ, Vaziri ND, Yu XY, Zhang L, Su W, Bai X, Zhao YY (2017) Combined clinical phenotype and lipidomic analysis reveals the impact of chronic kidney disease on lipid metabolism. J Proteome Res 16:1566–1578PubMedCrossRef

go back to reference Baek J, He C, Afshinnia F, Michailidis G, Pennathur S (2022) Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease. Nat Rev Nephrol 18:38–55PubMedCrossRef Baek J, He C, Afshinnia F, Michailidis G, Pennathur S (2022) Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease. Nat Rev Nephrol 18:38–55PubMedCrossRef

go back to reference Noels H, Lehrke M, Vanholder R, Jankowski J (2021) Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol 17:528–542PubMedCrossRef Noels H, Lehrke M, Vanholder R, Jankowski J (2021) Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol 17:528–542PubMedCrossRef

go back to reference Brady TM, Schneider MF, Flynn JT, Cox C, Samuels J, Saland J, White CT, Furth S, Warady BA, Mitsnefes M (2012) Carotid intima-media thickness in children with CKD: results from the CKiD study. Clin J Am Soc Nephrol 7:1930–1937PubMedPubMedCentralCrossRef Brady TM, Schneider MF, Flynn JT, Cox C, Samuels J, Saland J, White CT, Furth S, Warady BA, Mitsnefes M (2012) Carotid intima-media thickness in children with CKD: results from the CKiD study. Clin J Am Soc Nephrol 7:1930–1937PubMedPubMedCentralCrossRef

go back to reference Azukaitis K, Kirchner M, Doyon A, Litwin M, Bayazit A, Duzova A, Canpolat N, Jankauskiene A, Shroff R, Melk A, Querfeld U, Schaefer F, 4C Study Investigators (2022) Arterial stiffness and chronic kidney disease progression in children. Clin J Am Soc Nephrol 17:1467–1476PubMedPubMedCentralCrossRef Azukaitis K, Kirchner M, Doyon A, Litwin M, Bayazit A, Duzova A, Canpolat N, Jankauskiene A, Shroff R, Melk A, Querfeld U, Schaefer F, 4C Study Investigators (2022) Arterial stiffness and chronic kidney disease progression in children. Clin J Am Soc Nephrol 17:1467–1476PubMedPubMedCentralCrossRef

go back to reference Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members (2014) KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85:1303–1309PubMedCrossRef Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members (2014) KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85:1303–1309PubMedCrossRef

go back to reference Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C (2018) Lipid management in patients with chronic kidney disease. Nat Rev Nephrol 14:727–749PubMedCrossRef Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C (2018) Lipid management in patients with chronic kidney disease. Nat Rev Nephrol 14:727–749PubMedCrossRef

go back to reference Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J, American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research (2006) Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the Interdisciplinary working group on quality of care and outcomes research: endorsed by the American Academy of Pediatrics. Circulation 114:2710–2738PubMedCrossRef Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J, American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research (2006) Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the Interdisciplinary working group on quality of care and outcomes research: endorsed by the American Academy of Pediatrics. Circulation 114:2710–2738PubMedCrossRef

go back to reference Ramesh PL, Khandelwal P, Lakshmy R, Sinha A, Bagga A, Hari P (2023) Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2–5. Pediatr Nephrol 38:2763–2770PubMedCrossRef Ramesh PL, Khandelwal P, Lakshmy R, Sinha A, Bagga A, Hari P (2023) Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2–5. Pediatr Nephrol 38:2763–2770PubMedCrossRef

go back to reference German CA, Liao JK (2023) Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol 97:1529–1545PubMedPubMedCentralCrossRef German CA, Liao JK (2023) Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol 97:1529–1545PubMedPubMedCentralCrossRef

go back to reference Kadatane SP, Satariano M, Massey M, Mongan K, Raina R (2023) The role of inflammation in CKD. Cells 12:1581PubMedPubMedCentralCrossRef Kadatane SP, Satariano M, Massey M, Mongan K, Raina R (2023) The role of inflammation in CKD. Cells 12:1581PubMedPubMedCentralCrossRef